Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

ConclusionsIn patients with ATTR-CM, tafamidis was associated with a lower rate of CV-related hospitalizations and shorter length of hospital stay. Timely diagnosis and treatment with tafamidis could further decrease the total number of CV-related hospitalization days per year.CLINICALTRIALS.gov IdentifierNCT01994889.

Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research